HEB Hemispherx BioPharma Inc.

+0.34  (+9%)
Previous Close 3.98
Open 4.21
Price To Book 6.75
Market Cap 9,506,540
Shares 2,200,588
Volume 241,446
Short Ratio 0.37
Av. Daily Volume 206,077

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL February 4, 2013.
Phase 1 data due 2020.
Ampligen, Intron A, celecoxib and pembrolizumab
Triple-Negative Breast Cancer
Phase 2 data due 2020.
Ampligen, Intron A, and celecoxib
Colorectal cancer
Phase 2 initiation of patient dosing announced June 12, 2019 with data due 2021.
Ampligen, cisplatin and pembrolizumab
Ovarian cancer
Phase 2 trial to commence June 2019.
Ampligen, Intron A
Prostate Cancer
Phase 1 interim data likely 2H 2019.
Ampligen, cisplatin and pembrolizumab
Ovarian cancer

Latest News

  1. Hemispherx Biopharma Inc (HEB) Exec. Vice Chairman/CEO/Pres. Thomas K. ...
  2. Have Insiders Been Buying Hemispherx Biopharma, Inc. (NYSEMKT:HEB) Shares?
  3. Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program
  4. Company News For Jun 13, 2019
  5. Hemispherx Biopharma Announces First Patient Treated in Phase 2 Ovarian Cancer Clinical Trial Evaluating Ampligen in Combination with Pembrolizumab and Cisplatin
  6. Hemispherx Biopharma Stockholders Approve Reverse Stock Split
  7. Hemispherx Reports 2019 First Quarter Financial Results
  8. Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center Edges Closer for Hemispherx Biopharma
  9. Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center
  10. Hemispherx Biopharma's CEO to Attend BioFlorida Inc.’s 2019 Celebration of Biotechnology
  11. Hemispherx Links Stanford’s ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization
  12. Hemispherx To Be Transparent on the Development of Ampligen and Announced Significant Progress
  13. Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program
  14. Hemispherx Biopharma's CEO to Present at Planet MicroCap Showcase 2019
  15. MicroCap Review Magazine Spring 2019 Issue Now Available
  16. Hemispherx Biopharma Names Ellen Lintal as New Chief Accounting Officer
  17. Some Hemispherx Biopharma (NYSEMKT:HEB) Shareholders Have Copped A 96% Share Price Wipe Out
  18. Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx’ Ampligen and Pembrolizumab
  19. Hemispherx Reports 2018 Year-end Financial Results